All Type of News
Multinational companies active in conducting domestic clinical trials
It was observed multinational companies have actively conducted domestic clinical trials to develop new drugs.
According to the clinical trial approval report of the Ministry of Food and Drug Safety, 6 multinational ...
Celltrion Healthcare receives Tower of $300 Million Exports for the first time as a pharmaceutical companyCelltrion Healthcare was awarded the ‘Tower of $300 Million Exports(1 July 2014 to 30 June 2015)’ at the 2015 52nd Trade Day ceremony hosted by the Korea International Trade Ass...
|
Chong Kun Dang exclusively sells female sexual dysfunction treatment for the first time in KoreaChong Kun Dang(CEO Young-joo Kim) established an exclusive sales agreement of a female sexual dysfunction treatment with S1 Biopharma, a U.S. company, at the Chong Kun Dang head...
|
Firm patent wall of ‘Nexavar,’ a liver cancer treatment, to overcome for domestic companies
The challenges of domestic pharmaceutical companies to nullify the period extension of the substance patent of ‘Nexavar(sorafenib tosilate, Bayer),’ a liver cancer targeted treatment, have encountered difficulties.
A...
Medical expenses for gout, rapidly increased to KRW 59.4 billion in a year
As the number of patients with extremely painful gout was significantly increased, the year-long medical expenses for the disease reached KRW 59.4 billion. In particular, most of the patients were men in 30s.
The Nat...
Samsung Bioepis hurries to launch pharmaceutical products, acquiring the second product approval
Samsung Bioepis announced acquisition of product approval of Renflexis(Remicade biosimilar), an autoimmune disease treatment, from the Ministry of Food and Drug Safety on the 4th.
Thus, Samsung Bioepis has become a c...
MSD Korea launches Brenzys™ in Korea for the first timeOn the 3rd, MSD Korea(CEO Dong-wook Hyun) announced Samsung Bioepis will launch Brenzys™, a biosimilar the company developed and commercializes, for the first time in the world....
|
Amgen Korea announces approval of Blincyto as acute lymphoblastic leukemia treatmentAmgen Korea announced commercialization approval of Blincyto Inj 35μg(generic name: blinatumomab), an acute lymphoblastic leukemia (ALL: Acute Lymphoblastic Leukemia) treatment,...
|
“Special Act on Medical Students is just another Regulatory Guillotine”
The Korean Hospital Association criticized the ‘Act of Improving Training Environments and Positions of Medical Students(Special Act on Medical Students)’ on the 4th, “It was an action which ignores the reality of the...
Market capitalization of biopharmaceutical companies exceeds KRW 1 trillion
It was observed the average R&D investment ratio of listed biopharmaceutical companies to sales exceeded 20%.
The phenomenon seems biopharmaceutical ventures have to spend an enormous amount of R&D expenses, but have...
